Cas 602306-29-6 AZD5438 CDK Inhibitors Cyclin Dependent Kinase Inhibitors
Cas 602306-29-6 AZD5438 CDK Inhibitors Cyclin Dependent Kinase Inhibitors
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
AddThis Sharing Buttons
Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:AZD5438 |
Purity:98% min |
|
CAS NO:602306-29-6 |
Solubility:DMSO100 mg/mL (269.21 mM) |
|
Molecular Formula:C18H21N5O2S |
Package:Package according to customer requirements |
|
Molecular Weight:371.457 |
Storage:Store at -20℃ |
Quality control
Remarks
AZD5438 is a potent inhibitor of cyclin-dependent kinase (cdk) 1, 2, and 9 (IC(50), 16, 6, and 20 nmol/L, respectively). In vitro, AZD5438 showed significant antiproliferative activity in human tumor cell lines (IC(50) range, 0.2-1.7 micromol/L), causing inhibition of the phosphorylation of cdk substrates pRb, nucleolin, protein phosphatase 1a, and RNA polymerase II COOH-terminal domain and blocking cell cycling at G(2)-M, S, and G(1) phases.
Related Products
Flavopiridol HCL; Flavopiridol; THZ1; BMS-863233 HCl; Dinaciclib; Seliciclib; PalbociclibIsethionate; PHA-793887; RO-3306; Abemaciclib mesylate; Abemaciclib; JNJ-7706621
References
[1].Byth KF, et al. AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Mol Cancer Ther. 2009 Jul;8(7):1856-66. Epub 2009 Jun 9.
[2].Raghavan P, et al. AZD5438, an Inhibitor of Cdk1, 2, and 9, Enhances the Radiosensitivity of Non-Small Cell Lung Carcinoma Cells. Int J Radiat Oncol Biol Phys. 2012 Jul 12.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.